Expert: Ligand targeting prostate-specific membrane antigen (PSMA) conjugated to therapeutic radioisotope (Lu-177 or Ac-225)

Everyday: Targets a protein on prostate cancer cells to deliver radiation directly to tumors

Targets: ["PSMA"]

Actinium-225-labeled PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. Alpha-emitting radiopharmaceutical providing more potent DNA damage than beta-emitting Lu-177 PSMA-617 (Pluvicto); for patients progressing after Lu-177.